When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.
www.bloomberg.com
#Ozempic #Makers #Plight #Shows #Managing #Markets #Counts
Ozempic Maker’s Plight Shows Managing Markets Counts Too
